These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29161283)

  • 1. Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
    Igarashi K; Yamashita K; Katoh H; Kojima K; Ooizumi Y; Nishizawa N; Nishiyama R; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Watanabe M
    PLoS One; 2017; 12(11):e0188178. PubMed ID: 29161283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer.
    Minatani N; Waraya M; Yamashita K; Kikuchi M; Ushiku H; Kojo K; Ema A; Nishimiya H; Kosaka Y; Katoh H; Sengoku N; Tanino H; Sidransky D; Watanabe M
    PLoS One; 2016; 11(1):e0144862. PubMed ID: 26785325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer.
    Harada H; Hosoda K; Moriya H; Mieno H; Ema A; Ushiku H; Washio M; Nishizawa N; Ishii S; Yokota K; Tanaka Y; Kaida T; Soeno T; Kosaka Y; Watanabe M; Yamashita K
    PLoS One; 2019; 14(4):e0214872. PubMed ID: 30934021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma.
    Ushiku H; Yamashita K; Katoh H; Ema A; Minatani N; Kikuchi M; Kojo K; Yokoi K; Tanaka T; Nishizawa N; Ishii S; Hosoda K; Moriya H; Mieno H; Katada N; Kikuchi S; Watanabe M
    Dis Esophagus; 2017 Feb; 30(2):1-9. PubMed ID: 27629777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.
    Nakamoto S; Kumamoto Y; Igarashi K; Fujiyama Y; Nishizawa N; Ei S; Tajima H; Kaizu T; Watanabe M; Yamashita K
    PLoS One; 2018; 13(10):e0205864. PubMed ID: 30325974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Prognostic Relevance of Promoter DNA Methylation of
    Tanaka Y; Kosaka Y; Waraya M; Yokota K; Harada H; Kaida T; Kikuchi M; Minatani N; Nishimiya H; Katoh H; Sengoku N; Watanabe M; Yamashita K
    Anticancer Res; 2019 May; 39(5):2289-2298. PubMed ID: 31092420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.
    Nishizawa N; Harada H; Kumamoto Y; Kaizu T; Katoh H; Tajima H; Ushiku H; Yokoi K; Igarashi K; Fujiyama Y; Okuwaki K; Iwai T; Watanabe M; Yamashita K
    Cancer Sci; 2019 Sep; 110(9):2846-2855. PubMed ID: 31325200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN).
    Fujiyama Y; Kumamoto Y; Nishizawa N; Nakamoto S; Harada H; Yokota K; Tanaka Y; Igarashi K; Oiki H; Okuwaki K; Iwai T; Kajita S; Takahashi H; Tajima H; Kaizu T; Sasaki J; Watanabe M; Yamashita K
    Ann Surg Oncol; 2020 Oct; 27(10):4007-4016. PubMed ID: 32144623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
    Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
    Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.
    Deckers IA; Schouten LJ; Van Neste L; van Vlodrop IJ; Soetekouw PM; Baldewijns MM; Jeschke J; Ahuja N; Herman JG; van den Brandt PA; van Engeland M
    Clin Cancer Res; 2015 Aug; 21(15):3492-500. PubMed ID: 25904753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Status of CDO1 Gene May Reflect Chemosensitivity in Colon Cancer with Postoperative Adjuvant Chemotherapy.
    Yokoi K; Harada H; Yokota K; Ishii S; Tanaka T; Nishizawa N; Shimazu M; Kojo K; Miura H; Yamanashi T; Sato T; Nakamura T; Watanabe M; Yamashita K
    Ann Surg Oncol; 2019 Feb; 26(2):406-414. PubMed ID: 30311169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma.
    Kojima K; Yamashita K; Ushiku H; Katoh H; Ishii S; Tanaka T; Yokoi K; Suzuki M; Ooizumi Y; Igarashi K; Hosoda K; Moriya H; Mieno H; Katada N; Tanabe S; Watanabe M
    Dis Esophagus; 2017 Mar; 30(3):1-9. PubMed ID: 28184414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer.
    Harada H; Soeno T; Yokoi K; Nishizawa N; Ushiku H; Hosoda K; Hiki N; Yamashita K
    J Surg Res; 2020 Dec; 256():404-412. PubMed ID: 32777557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
    Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
    BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis.
    Takahashi T; Shivapurkar N; Riquelme E; Shigematsu H; Reddy J; Suzuki M; Miyajima K; Zhou X; Bekele BN; Gazdar AF; Wistuba II
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6126-33. PubMed ID: 15447999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WNT inhibitory factor 1 promoter hypermethylation is an early event during gallbladder cancer tumorigenesis that predicts poor survival.
    Lin B; Hong H; Jiang X; Li C; Zhu S; Tang N; Wang X; She F; Chen Y
    Gene; 2017 Jul; 622():42-49. PubMed ID: 28438695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.
    Yang Y; Fan YC; Gao S; Dou CY; Zhang JJ; Sun FK; Wang K
    Tohoku J Exp Med; 2014 Mar; 232(3):187-94. PubMed ID: 24646840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress and deregulations in base excision repair pathway as contributors to gallbladder anomalies and carcinoma - a study involving North-East Indian population.
    Singh N; Kazim SN; Sultana R; Tiwari D; Borkotoky R; Kakati S; Nath Das N; Kumar Saikia A; Bose S
    Free Radic Res; 2019 May; 53(5):473-485. PubMed ID: 31117842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of cancer specific methylation of the CDO1 gene in small bowel cancer.
    Kojima K; Nakamura T; Ooizumi Y; Igarashi K; Tanaka T; Yokoi K; Ishii S; Nishizawa N; Katoh H; Kosaka Y; Sato T; Watanabe M; Yamashita K
    PLoS One; 2019; 14(1):e0211108. PubMed ID: 30677088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA diagnosis of peritoneal fluid cytology test by CDO1 promoter DNA hypermethylation in gastric cancer.
    Ushiku H; Yamashita K; Ema A; Minatani N; Kikuchi M; Kojo K; Yokoi K; Tanaka T; Nishizawa N; Ishii S; Hosoda K; Moriya H; Mieno H; Katada N; Kikuchi S; Katoh H; Watanabe M
    Gastric Cancer; 2017 Sep; 20(5):784-792. PubMed ID: 28243814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.